As an international company listed on the stock exchanges in Copenhagen and New York, Novo Nordisk is subject to the Danish Corporate Governance Recommendations designated by Nasdaq Copenhagen, and - as a foreign listed private issuer – to the Corporate Governance Listing Standards on New York Stock Exchange as stated in the Listed Company Manual.
Revised Danish Corporate Governance Recommendations were introduced in November 2017.?Novo Nordisk adheres to all of the Danish Corporate Governance Recommendations designated by Nasdaq Copenhagen except the following four:
As a foreign listed private issuer Novo Nordisk is in compliance with the corporate governance standards of the New York Stock Exchange, where Novo Nordisk’s ADRs are listed.
For a detailed review of Novo Nordisk's compliance with, deviations from and explanations to all applicable recommendations please see the following:
In accordance with art. 107b of the Danish Financial Statements Act Novo Nordisk has prepared a Statutory Corporate Governance Report (in Danish "Lovpligtig redeg?relse for virksomhedsledelse, jf. ?rsregnskabslovens § 107 b").
The Corporate Governance Reports for 2014, 2015, 2016, 2017 and 2018 can be found below: